CRVO

New technology takes invisibility cloak off in retinal imaging
New technology takes invisibility cloak off in retinal imagingNew imaging technologies, such as ultra-wide-field fluorescein angiography and optical coherence tomography angiography, are providing more details about retinal diseases than previous imaging technologies, leading to better understanding of disease processes.
A clinical perspective of neovascular glaucomaNeovascular glaucoma is a potentially devastating ocular consequence of pathologic neovascularization of intraocular tissue. The symptoms include vision loss caused by both the underlying etiology (such as retinal vascular disease) as well as increased intraocular pressure (IOP), often accompanied by corneal edema, hyphema, or vitreous hemorrhage.
Health Canada approves Eyelea for DME treatmentHealth Canada recently approved Eylea (aflibercept, Regeneron) for the treatment of diabetic macular edema (DME).
STAAR Surgical, Regeneron expanding products to JapanSTAAR Surgical and Regeneron Pharmaceuticals—in collaboration with Bayer Healthcare—are making strides in Japan.
FDA accepts Eylea sBLAThe FDA has accepted for standard review Regeneron Pharmaceuticals Inc.’s supplemental Biologics License Application (sBLA) of aflibercept (Eylea) for the treatment of diabetic macular edema (DME).
Regeneron injection gains European approvalRegeneron Pharmaceuticals’ new treatment for visual impairment due to macular edema secondary to central retinal vein occlusion (CRVO) has been approved by the European Commission.